Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nina Žigart"'
Autor:
Nina Žigart, Zdenko Časar
Publikováno v:
ACS Omega, Vol 5, Iss 28, Pp 17726-17742 (2020)
Externí odkaz:
https://doaj.org/article/61b967be33e74f26b041dedb0fbd725a
Publikováno v:
Crystals, Vol 11, Iss 3, p 261 (2021)
Venetoclax is an orally bioavailable, B-cell lymphoma-2 selective inhibitor used for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. Venetoclax’s crystal structure was until now determined only
Externí odkaz:
https://doaj.org/article/5b045b0aa36f47faac15b4921e18cd28
Publikováno v:
Pharmaceutics, Vol 12, Iss 7, p 639 (2020)
Venetoclax is an orally bioavailable, B-cell lymphoma-2 (BCL-2) selective inhibitor, used for the treatment of various types of blood cancers, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this study we investiga
Externí odkaz:
https://doaj.org/article/6d416e0b76d343bd87be443c869a3f74
Publikováno v:
Advanced Synthesis & Catalysis. 363:2396-2402
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5f7e81c407b58dbfb4f6657c367913a
https://doi.org/10.1002/adsc.202001350
https://doi.org/10.1002/adsc.202001350
Publikováno v:
Organic Process Research & Development. 23:1784-1802
This review presents the Analytical Quality by Design (AQbD) concept, an extension of Quality by Design (QbD), which was introduced in 2004 by the U.S. Food and Drug Administration (FDA) and approv...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cbacd24309c653974b3428eaaede699
https://doi.org/10.1021/acs.oprd.9b00238
https://doi.org/10.1021/acs.oprd.9b00238
Autor:
Nina Žigart, Zdenko Časar
Publikováno v:
Expert Opinion on Therapeutic Patents. 29:487-496
Studies presented in patents show that a novel chemotherapeutic agent, venetoclax, might be useful in additional therapeutic indications. Venetoclax is approved in America for the treatment of patients with chronic lymphocytic leukemia (CLL) or small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2f1c9da48d8c268763d2af14155326
https://doi.org/10.1080/13543776.2019.1627327
https://doi.org/10.1080/13543776.2019.1627327
Publikováno v:
Crystals, Vol 11, Iss 261, p 261 (2021)
Crystals
Volume 11
Issue 3
Crystals
Volume 11
Issue 3
Venetoclax is an orally bioavailable, B-cell lymphoma-2 selective inhibitor used for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. Venetoclax’s crystal structure was until now determined only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67295573a575f9ca8713715b471e4519
https://www.mdpi.com/2073-4352/11/3/261
https://www.mdpi.com/2073-4352/11/3/261